Application of Amiodarone and Cedilan in the Treatment of Patients with Arrhythmia after Esophageal and Lung Cancer

Abstract

Objective. To explore the effect of amiodarone and cedilan in the treatment of patients with arrhythmia after esophageal and lung cancer. Methods. The data of 60 patients with postoperative complications of arrhythmias after esophageal and lung cancer from January 2018 to July 2021 were retrospectively analyzed and divided into an observation group (n = 30) and control group (n = 30) according to the random number grouping principle. The former group was treated with amiodarone, and the latter group received cedilan. Results. The effective rate of treatment was significantly higher in the observation group than the control group ( $P<0.05$ ). The observation group had the drug onset time obviously shorter than the control group ( $P<0.001$ ). The average ventricular rate after treatment in the observation group was remarkably lower than the control group ( $P<0.001$ ). The observation group exhibited obviously better cardiac function after treatment as compared to the control group ( $P<0.05$ ). The incidence of adverse reactions in the observation group was notably lower than the control group ( $P<0.05$ ). Moreover, the observation group had less stress after treatment than the control group ( $P<0.001$ ). The blood pressure level of the observation group after treatment was significantly better than the control group ( $P<0.05$ ). Conclusion. Amiodarone can relieve stress in patients with arrhythmia following esophageal and lung cancer surgery, stabilize blood pressure, and mitigate arrhythmia symptoms. Our findings are worthy of promotion and application in clinic.